Based on the iShares Healthcare Innovation UCITS ETF USD (Acc) stock forecast from 0 analysts, the average analyst target price for iShares Healthcare Innovation UCITS ETF USD (Acc) is not available over the next 12 months. iShares Healthcare Innovation UCITS ETF USD (Acc)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of iShares Healthcare Innovation UCITS ETF USD (Acc) is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, iShares Healthcare Innovation UCITS ETF USD (Acc)’s stock price was USD 7.29. iShares Healthcare Innovation UCITS ETF USD (Acc)’s stock price has changed by +0.87% over the past week, -4.43% over the past month and -3.86% over the last year.
No recent analyst target price found for iShares Healthcare Innovation UCITS ETF USD (Acc)
No recent average analyst rating found for iShares Healthcare Innovation UCITS ETF USD (Acc)
Company Overview iShares Healthcare Innovation UCITS ETF USD (Acc)
Stock Target Advisor's fundamental analysis for iShares Healthcare Innovation UCITS ETF USD (Acc)'s stock is Neutral.
Unfortunately we do not have enough data on HEAL:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on HEAL:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on HEAL:LSE's stock to indicate if its overvalued.
The last closing price of HEAL:LSE's stock was USD 7.29.
The most recent market capitalization for HEAL:LSE is USD 1.14B.
Unfortunately we do not have enough analyst data on HEAL:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains iShares Healthcare Innovation UCITS ETF USD (Acc)'s stock.
Sorry, we do not have any data on the number of employees for iShares Healthcare Innovation UCITS ETF USD (Acc).
Sorry we do not have any infomation available on iShares Healthcare Innovation UCITS ETF USD (Acc)'s address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HEAL:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
